Intravitreal administration of bevacizumab in the treatment of choroidal metastasis in a patient with erlotinib-failed pulmonary adenocarcinoma
Intravitreal administration of bevacizumab in the treatment of choroidal metastasis in a patient with erlotinib-failed pulmonary adenocarcinoma
复制标题
DOI：
10.1016/j.lungcan.2012.02.020
复制
发表时间：
2012-06-01
期刊：
影响因子：
5.3
通讯作者：
Fan, Wen-Hsiung
中科院分区：
文献类型：
--
作者：
Lai, Chun-Liang;Fan, Kuo-Sheng;Fan, Wen-Hsiung
脉络膜转移是不常见的，通常在相对晚期的癌症状态下被发现。肺癌患者诊断脉络膜转移后的中位生存期仅为1.9个月。一旦全身治疗失败，就没有有效的局部治疗方法来挽救视力。玻璃体内贝伐单抗的标签外使用在全球范围内普遍用于治疗VEGF介导的脉络膜视网膜疾病。我们在此证明玻璃体内注射贝伐单抗具有显著和持久的反应。与之前的类似报告不同，我们的患者一线和二线治疗均失败。(C)2012爱思唯尔爱尔兰有限公司保留所有权利。
Choroidal metastasis is uncommon and usually identified in a relatively advanced cancer status. The median survival after diagnosing choroid metastasis in lung cancer patients was only 1.9 months. Once failed to systemic treatment, there was no effective local treatment for saving visual acuity. The off-label use of intravitreal bevacizumab was popular in treating VEGF-mediated chorioretinal diseases worldwide. We here demonstrate a dramatic and durable response to intravitreal bevacizumab. Unlike the previous similar reports, our patient had failed both first- and second-line therapies. (C) 2012 Elsevier Ireland Ltd. All rights reserved.